CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
// Fenne L. Komdeur 1, * , Maartje C.A. Wouters 1, 2, * , Hagma H. Workel 1 , Aline M. Tijans 1 , Anouk L.J. Terwindt 1 , Kim L. Brunekreeft 1 , Annechien Plat 1 , Harry G. Klip 1 , Florine A. Eggink 1 , Ninke Leffers 1 , Wijnand Helfrich 3 , Douwe F. Samplonius 3 , Edwin Bremer 3 , G. Bea A. Wisman 1 , Toos Daemen 2 , Evelien W. Duiker 4 , Harry Hollema 4 , Hans W. Nijman 1, # , Marco de Bruyn 1, # 1 University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, The Netherlands 2 University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, The Netherlands 3 University of Groningen, University Medical Center Groningen, Department of Surgery, The Netherlands 4 University of Groningen, University Medical Center Groningen, Department of Pathology, The Netherlands * These authors have contributed equally to this work # MB and HWN share senior authorship Correspondence to: Hans W. Nijman, email: h.w.nijman@umcg.nl Keywords: tumor-infiltrating lymphocytes, high-grade serous ovarian cancer, CD103, TGF-β, cancer immunotherapy Received: May 06, 2016 Accepted: September 02, 2016 Published: September 16, 2016 ABSTRACT CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific epithelial infiltration and a prolonged survival in high-grade serous epithelial ovarian cancer (HGSC). However, whether these cells are induced as part of an ongoing anti-HGSC immune response or represent non-specifically expanded resident or mucosal lymphocytes remains largely unknown. In this study, we first confirmed that CD103+ TIL from HGSC were predominantly localized in the cancer epithelium and were strongly correlated with an improved prognosis. We further demonstrate that CD103+ TIL were almost exclusively CD3+ TCRαβ+ CD8αβ+ CD4- T cells, but heterogeneously expressed T cell memory and differentiation markers. Activation of peripheral T cells in the presence of HGSC was sufficient to trigger induction of CD103 in over 90% of all CD8+ cells in a T cell receptor (TCR)- and TGFβR1-dependent manner. Finally, CD103+ TIL isolated from primary HGSC showed signs of recent activation and dominantly co-expressed key immunotherapeutic targets PD-1 and CD27. Taken together, our data indicate CD103+ TIL in HGSC are formed as the result of an adaptive anti-tumor immune response that might be reactivated by (dual) checkpoint inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331
Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402711 · Cited by 622 · cited 1×
“In NSCLC, CD103+ TIL were found to be of a homogeneous CD69+ CD62L− CD28− CD27+ CD45RA+ CD45RO+ CCR7− subtype [16].”
Cited by
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“The presence of tumor-resident CD103+ TILs could also represent a good candidate marker of response to immunotherapy as this TIL population seems to express PD-1 (Djenidi et al., 2015; Komdeur et al., 2016).”
BackgroundTissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Enamorado, M., Iborra, S., Priego, E., Cueto, F. J., Quintana, J. A., Martínez-Cano, S., Mejías-Pérez, E., Esteban, M., Melero, I., Hidalgo, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16073 · Cited by 293
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Tissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 262
Self-citationQu, Q.-X., Zhu, X.-Y., Du, W.-W., Wang, H.-B., Shen, Y., Zhu, Y.-B., & Chen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00577 · Cited by 30
“With regards to phenotype of resident T cells, other studies have suggested that up-regulation of CD103 is mainly the result of TCR signaling upon contact with cancer cells (36).”
Result
Metadata
- Authors
- Komdeur, F. L., Wouters, M. C. A., Workel, H. H., Tijans, A. M., Terwindt, A. L. J., Brunekreeft, K. L., Plat, A., Klip, H. G., Eggink, F. A., Leffers, N., Helfrich, W., Samplonius, D. F., Bremer, E., Wisman, G. B. A., Daemen, T., Duiker, E. W., Hollema, H., Nijman, H. W., & de Bruyn, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-16
- Volume
- 7
- Issue
- 46
- Pages
- 75130-75144
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2519636301
- Cited by
- 69
- References
- 2
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.